Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based and pathological fi ndings
Introduction
Many institutions are using large radiotherapy fi elds for elective nodal irradiation in chemoradiotherapy for esophageal cancer. However, it has been suggested that locoregional recurrence due to missed targets and treatment-related toxicities caused by large fi elds of radiation still occur in a substantial proportion of patients, and thus more accurate radiotherapy targeting is needed to improve locoregional control and reduce toxicity.
1 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) is frequently used to detect the primary tumor and metastasis to lymph nodes, and is reported to be useful to supplement computed tomography (CT) in the staging of esophageal cancer. [2] [3] [4] [5] [6] However, Yoon et al. 7 reported that this imaging modality had limited effi cacy for presurgical diagnosis. In their study, Yoon et al. compared CT-and FDG-PET-based clinical diagnoses with the pathological diagnoses after surgery and reported that both FDG-PET and CT had low sensitivity for depicting nodal metastasis. Recently, Yuan et al. 8 reported that PET/ CT was more effective than PET alone for assessing the involvement of locoregional lymph nodes in thoracic esophageal squamous cell carcinoma.
In a prospective trial of preoperative chemoradiotherapy for esophageal cancer, FDG-PET was shown to be useful in the staging and prediction of prognosis by detecting occult metastasis. 9 However, Vrieze et al. 10 showed that FGD-PET alone could not be used for treatment planning because the chance of a false-negative result on FGD-PET was not negligible, and thus the target volume should not be reduced based on a negative FDG-PET fi nding in a region with nodes that are suspect by other modalities. It has been shown that CT and FDG-PET image fusion has an impact on the planning of treatment and management of esophageal carcinoma, by altering the choice of gross tumor volume (GTV). 11 Similarly, Gondi et al. 12 suggested Abstract Background. We aimed to determine the appropriateness of adding 18F-fl uorodeoxyglucose (FDG)-positronemission tomography (PET) to computed tomography (CT) and other pre-existing diagnostic imaging modalities for detecting subclinical lymph node metastasis of esophageal cancer, by comparing images from these modalities with the results of histopathological analysis. Methods. Twenty patients who received radical surgery for squamous cell carcinoma of the esophagus were examined by PET-CT, and endoscopic ultrasound (EUS) examination before surgery. Based on these diagnostic modalities, the clinical target volume (CTV) was set as the gross tumor volume (GTV) plus a 1-cm margin. Histopathological diagnosis was performed in all patients immediately after resection.
Results. Fifty-three (3.0%) of 1764 nodes in the 20 patients were histopathologically positive for cancer cells. that a hybrid FDG-PET/CT scanner had an impact on radiotherapy planning for esophageal cancer and non-small cell lung cancer. In this study, we investigated the appropriateness of hybrid PET/CT for determining the clinical target volume (CTV) in patients with squamous cell carcinoma of the esophagus, by comparing the radiological diagnosis before surgery and the pathological diagnosis. We also compared the effi cacy of hybrid PET/CT with that of CT alone, FDG-PET alone, and the combination of CT and endoscopic ultrasound (EUS) for CTV determination. All patients received a diagnostic workup consisting of CT, endoscopy and EUS, and FDG-PET within 2 weeks. A high-speed multidetector raw CT scan (ROBUSTO; Hitachi Medical, Tokyo, Japan) was used, with a slice thickness of 5 mm and an interval of 5 mm. An endoscopist performed the EUS (EU-M2000; Olympus Medical Systems, Tokyo, Japan) and provided a written report of the EUS results for all patients. F-18 FDG was purchased from Nihon Medi-Physics, (Tokyo, Japan). It was intravenously injected in patients who were instructed to fast for at least 4 h before PET imaging. Sixty minutes after the FDG injection, an attenuation-corrected whole-body image (threedimensional [3D] mode) from the top of the skull to the proximal thighs was obtained at one bed position per 2.0 min using PET/CT (GEMINI-GXL; Philips, Amsterdam, the Netherlands).
Patients, materials, and methods
Diagnostic specialists reviewed each image independently without reference to the other images. A radiologist examined each node and diagnosed it as positive if the maximum diameter was larger than 1.0 cm without calcifi cation on transaxial CT. On PET-CT, each node was diagnosed as positive if the node showed increased FDG uptake relative to the surrounding tissue. The standardized uptake value (SUV) was used only for a reference. A cutoff SUV was not set. On EUS, an endosonographer diagnosed a node as positive if the visible lymph node showed a size of more than 5 mm and its shape was round or oval, with a mixed/hyperechoic internal texture.
A radiation oncologist determined the CTV by adding a 1.0-cm margin around the GTV, including local tumor and lymphatic involvement, based on either CT alone, CT with EUS, PET-CT alone, or PET-CT with EUS ( Fig. 1) . No other parameters were used, other than the GTV determined by each diagnostic image. The Japanese Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition 14 was used to describe the locations of the lymphatic involvement ( Table 1) . Analysis of the results was performed by grouping these lymphatic locations into the cervical and supraclavicular (A), mediastinal (B), and abdominal (C) regions. Surgery was performed within 3 weeks after the end of the diagnostic workup, in principle. A pathological diagnostic report was made by a pathologist for each surgical specimen, regarding local extent and lymphatic spread. The positivity of metastasis to the lymph nodes was examined histopathologically.
We fi rst calculated the diagnostic accuracy, sensitivity, and specifi city of CT and PET-CT. Fisher's exact test was used to compare categorical data. Adequacy of the CTV to cover subclinical pathological positive lymph node metastasis was compared among the different diagnostic workups after pathological investigation. The portal size of each radiotherapy plan was also examined.
Results
The surgical specimens of the 20 patients contained 1764 lymph nodes. Of the 1764 nodes, 53 (3.0%) were histopathologically positive for cancer cells. The numbers and locations of the lymph nodes are shown in Table 2 . The accuracies of thin-slice CT and conventional PET-CT according to the location of the lymph nodes were 95% and 85% for the cervical and supraclavicular region (A), 95% and 60% for the mediastinal region (B), and 65% and 60% for the abdominal region (C). The sensitivities were 100% and 50% (A), 86% and 14% (B), and 22% and 11% (C) for thin-slice CT and conventional PET-CT, respectively. The specifi cities were 94% and 94% (A), 69% and 85% (B), and 100% and 100% (C) for thin-slice CT and conventional PET-CT, respectively.
The number of patients with subclinical positive lymph node metastases that were not detected in the presurgical workup but were detected in the histopathological examination was determined for each of the combinations of imaging modalities. In the 20 patients, subclinical positive lymph node metastasis was not detected by CT alone (CT), in 8 patients, by CT and EUS (CT+EUS) in 5 patients, by PET-CT (PET-CT) in 7 patients or by PET-CT and EUS (PET-CT + EUS) in 5 patients.
To cover subclinical pathological positive lymph node metastasis, enlargement of the CTV was required for region (A) in one of eight patients with CT;, one of fi ve with CT+EUS, two of nine with PET-CT, and one of fi ve with PET-CT + EUS. For region (B), enlargement of the CTV was required in none of eight patients with CT, none of fi ve with CT+EUS, one of nine with PET-CT, and none of fi ve with PET-CT + EUS. For region (C), enlargement of the CTV was required in seven of eight patients with CT, four of fi ve with CT+EUS, six of nine with PET-CT, and four of fi ve with PET-CT + EUS (Table 3 ). There were no statistically signifi cant differences among the regions with the different modalities, but the results suggested that enlargement of the CTV was required more frequently for region (C) than for regions (A) and (B).
Discussion
The accuracy, specifi city, and sensitivity of FDG-PET for lymphatic metastasis of esophageal cancer in the present study were consistent with those of previously reported series. [15] [16] [17] [18] Meltzer et al. 15 have reported that FDG-PET had 35%-41% sensitivity and 90% specifi city, versus 63%-87% sensitivity and 14%-43% specifi city for CT. Räsänen et al. 16 have shown that the sensitivity for local peritumoral lymph node metastasis was 37% for PET and 89% for EUS, and the specifi city for local lymph node metastasis was 63% for PET, 66% for CT, and 75% for EUS. A systematic review showed that the pooled sensitivity and specifi city for the detection of locoregional metastases were 51% (95% confi dence interval [CI], 34%-69%) and 84% (95% CI, 76%-91%), respectively. 17 Katsoulis et al. 18 reported in a prospective study of the preoperative staging of thoracic esophageal and gastro-esophageal junction cancer that CT had 29% sensitivity and 67% specifi city, whereas FDG-PET had 71% sensitivity and 67% specifi city (P = 0.0412). In one of the largest series on squamous cell carcinoma (81 patients), Yoon et al. 7 showed that the sensitivity, specifi city, and accuracy, respectively, of CT were 11%, 95%, and 83%, whereas these values for FDG-PET were 30%, 90%, and 82% (P values, <0.001, 0.009, and 0.382, respectively). Although there is some variation in the literature, the sensitivity of PET for the detection of lymph node metastasis should be considered insuffi cient, although the specifi city may be better than that of a CT scan.
Yuan et al. 8 reported that PET/CT improved the sensitivity, accuracy, and negative predictive value of 18 F-FDG imaging in the assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. The sensitivity, specifi city, and accuracy of PET/CT were 93.90% (77/82 nodal groups), 92.06% (290/315), and 92.44% (367/397), respectively, whereas these values for PET were 81.71% (67/82), 87.30% (275/315), and 86.15% (342/397), respectively (P = 0.032, 0.067, and 0.006, respectively). However, our results did not show that the detection rate of subclinical lymph node metastasis improved with the addition of PET-CT for the cervical and supraclavicular, mediastinal, or abdominal regions. The PET-CT used in the present study was a state-of-the-art machine, and thus the same results would be expected even if we would have used one of the other PET-CT machines available now.
Previous studies have reported that the use of FDG-PET resulted in a change of the CTV margin around the GTV compared with that determined by CT. 1, 19 However, these same authors noted that determination of the CTV for the lymphatic region was a challenge even when using PET. Our results were consistent with their fi ndings. The detection rate of subclinical lymph node metastasis did not improve with the addition of PET-CT for either cervical and supraclavicular nodes, mediastinal, or abdominal regions. In clinical practice, a larger CTV including larger lymphatic regions is often used to cover unpredictable widespread lymphatic metastasis in esophageal cancer treatment. 1 Radiological examinations such as CT, PET, EUS, and CT-PET are not yet suffi cient for determination of the CTV for the lymphatic region. It is not conclusive whether we should treat all cervical, mediastinal, and abdominal lymphatic regions for a majority of patients, and this is a subject better left for future investigations. Enlargement of the CTV was required more frequently in the abdominal region (Table 3) . EUS has the potential to visualize a small lymph node metastasis located around the esophageal and gastric wall, though EUS also has a limitation in its penetration depth of about 5 cm. PET-CT is expected to perform better than CT in the detection of lymph node metastasis. In our present study, the result with PET-CT was not suffi cient for the detection of positive nodes. It may be that the amount of altered tissue glucose metabolism in subclinical lymph node metastases is not enough to be well visualized by extra-body PET detectors. FDG-PET/CT also has a limitation in detecting lymph node metastasis in deep abdominal lesions.
Our results suggest that PET-CT requires further improvement of its accuracy for the detection of positive nodes to improve accuracy in determining the CTV. Recently, a new PET with semiconductor detectors has been developed, and it is expected to have potential for the precise detection of small cancer metastases. 20 We need to continue to improve the various imaging modalities so that they can be used as reliable guides for radiotherapy.
In conclusion, it is not recommended to use FDG-PET or PET-CT alone to determine the CTV when all pathologically involved lymphatic regions are to be included in the CTV as a treatment strategy.
